国际专家共识:血小板P2Y12受体抑制剂转换治疗
该共识由北美和欧洲抗血小板治疗领域专家制定,概述P2Y12抑制剂药理学、转换模式与定义,并基于现有文献给出转换建议。针对双联抗血小板治疗中因临床情况需转换P2Y12抑制剂的安全性问题,指南未充分阐述,本共识为临床何时及如何转换提供指导。
要点
- 双联抗血小板治疗是急性冠脉综合征和经皮冠脉介入术后预防动脉血栓事件的首选。
- 口服P2Y12抑制剂(氯吡格雷、普拉格雷、替格瑞洛)及静脉坎格瑞洛使转换治疗成为可能。
- 临床常因多种因素转换P2Y12抑制剂,但安全性顾虑尚存,本共识提供转换指导。
核心结论
- 本专家共识概述P2Y12抑制剂药理学、转换模式与定义,并提供转换建议以指导临床实践。
研究设计与样本
- 由北美和欧洲抗血小板治疗基础、转化和临床科学专家制定的专家共识文件。
主要发现
- 双联抗血小板治疗是急性冠脉综合征和经皮冠脉介入患者预防动脉血栓事件的首选治疗。
- 不同口服P2Y12抑制剂及静脉坎格瑞洛使临床因特定情况转换治疗成为可能,但安全性顾虑存在。
- 实践指南未充分阐述如何转换治疗,导致临床医生在需要转换时缺乏指导。
临床怎么用
- 临床实践中可因多种因素转换P2Y12抑制剂,本共识为何时及如何转换提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability of different oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. The recent introduction of an intravenous P2Y12 inhibitor (cangrelor) further adds to the multitude of modalities and settings in which switching therapies may occur. In clinical practice, it is not uncommon to switch P2Y12 inhibitor, and switching may be attributed to a variety of factors. However, concerns about the safety of switching between these agents have emerged. Practice guidelines have not fully elaborated on how to switch therapies, leaving clinicians with limited guidance on when and how to switch therapies when needed. This prompted the development of this expert consensus document by key leaders from North America and Europe with expertise in basic, translational, and clinical sciences in the field of antiplatelet therapy. This expert consensus provides an overview of the pharmacology of P2Y12 inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y12 inhibitors.
引用
- Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017. PMID: 29084738. doi:10.1161/CIRCULATIONAHA.117.031164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。